BG101095A - Polyethyleneglycolizing reagents and compounds produced by them - Google Patents
Polyethyleneglycolizing reagents and compounds produced by themInfo
- Publication number
- BG101095A BG101095A BG101095A BG10109596A BG101095A BG 101095 A BG101095 A BG 101095A BG 101095 A BG101095 A BG 101095A BG 10109596 A BG10109596 A BG 10109596A BG 101095 A BG101095 A BG 101095A
- Authority
- BG
- Bulgaria
- Prior art keywords
- biologically active
- polyethyleneglycolizing
- reagents
- compounds
- compounds produced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Polyethers (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/259,413 US6552170B1 (en) | 1990-04-06 | 1994-06-14 | PEGylation reagents and compounds formed therewith |
PCT/US1995/007555 WO1995034326A1 (fr) | 1994-06-14 | 1995-06-14 | Reactifs de couplage de derives de polyethyleneglycol et composes formes avec ces derniers |
Publications (1)
Publication Number | Publication Date |
---|---|
BG101095A true BG101095A (en) | 1997-09-30 |
Family
ID=22984842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG101095A BG101095A (en) | 1994-06-14 | 1996-12-30 | Polyethyleneglycolizing reagents and compounds produced by them |
Country Status (15)
Country | Link |
---|---|
US (2) | US6552170B1 (fr) |
EP (1) | EP0758906A1 (fr) |
CN (1) | CN1158089A (fr) |
AU (1) | AU2828695A (fr) |
BG (1) | BG101095A (fr) |
BR (1) | BR9507999A (fr) |
CA (1) | CA2191971C (fr) |
CZ (1) | CZ357696A3 (fr) |
EE (1) | EE9600182A (fr) |
FI (1) | FI964985A (fr) |
HU (1) | HUT77529A (fr) |
NO (1) | NO965342L (fr) |
PL (1) | PL317894A1 (fr) |
SK (1) | SK159596A3 (fr) |
WO (1) | WO1995034326A1 (fr) |
Families Citing this family (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
NZ503548A (en) | 1996-02-09 | 2001-09-28 | Amgen Inc | A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus |
US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
JP4771563B2 (ja) | 1996-12-06 | 2011-09-14 | アムジエン・インコーポレーテツド | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
ES2207759T3 (es) | 1996-12-06 | 2004-06-01 | Amgen Inc. | Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf. |
DE69800640T2 (de) * | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US5912342A (en) * | 1997-08-12 | 1999-06-15 | Heinonen; Petri | Compounds a containing a solid support |
CN1084209C (zh) * | 1997-11-07 | 2002-05-08 | 复旦大学 | 一种高分子抗肿瘤导向药物及其制备方法 |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
CA2385533C (fr) * | 1999-10-04 | 2008-03-25 | Shearwater Corporation | Neuropeptides stabilises par des polymeres |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
KR20020056923A (ko) | 1999-11-18 | 2002-07-10 | 코르바스 인터내셔날, 인코포레이티드 | 엔도텔리아제를 암호화하는 핵산, 엔도텔리아제 및 이의용도 |
US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US7514239B2 (en) * | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
MXPA04000134A (es) | 2001-06-26 | 2005-06-06 | Abgenix Inc | Anticuerpos para ligandos de osteoprotegerina. |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
FR2835829B1 (fr) * | 2002-02-13 | 2007-09-14 | Centre Nat Rech Scient | Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications |
WO2003093433A2 (fr) * | 2002-05-02 | 2003-11-13 | Regents Of The University Of Minnesota | Matrice biologique a base de fibrine |
WO2003094965A2 (fr) * | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation de cellules souches neurales et de cellules progenitrices neurales |
US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
US20040002451A1 (en) | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
BRPI0314038B8 (pt) | 2002-09-06 | 2021-05-25 | Amgen Inc | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica |
CA2499075A1 (fr) * | 2002-09-16 | 2004-03-25 | Elusys Therapeutics, Inc. | Production de molecules bispecifiques au moyen de lieurs de polyethylene glycol |
DK1542714T3 (da) | 2002-09-18 | 2014-05-26 | Janssen Pharmaceuticals Inc | Fremgangsmåder til forøgelse af produktion af blodplader og hæmatopoietiske stamceller |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
EP1578842B1 (fr) * | 2002-12-31 | 2009-10-07 | Nektar Therapeutics Al, Corporation | Polymeres a terminaison maleimide hydrolytiquement stables |
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
PL213501B1 (pl) * | 2003-02-28 | 2013-03-29 | Ares Trading Sa | Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania |
US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
ES2335005T5 (es) * | 2003-03-05 | 2013-04-17 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (shasegp), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
NZ544924A (en) * | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
US7482376B2 (en) * | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
EP1663188B1 (fr) * | 2003-09-12 | 2016-08-10 | Newron Sweden AB | Traitement de maladies ou de lesions du systeme nerveux avec le fty720 |
EP1684791A4 (fr) | 2003-10-27 | 2009-07-01 | Amgen Inc | Compositions et procedes de modulation de la reaction immunitaire a un agent therapeutique immunogene |
WO2005056636A2 (fr) | 2003-12-03 | 2005-06-23 | Nektar Therapeutics Al, Corporation | Procede de preparation de polymeres fonctionnalises par maleimide |
US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
US20080131978A1 (en) * | 2004-02-03 | 2008-06-05 | Asahi Kasei Kabushiki Kaisha | Method of Detecting Analyte Using Magnetic Beads |
US20070264277A1 (en) | 2004-07-22 | 2007-11-15 | Dirk Behrens | Compositions and Methods of Use for Mgd-Csf in Disease Treatment |
US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
US20060045902A1 (en) * | 2004-09-01 | 2006-03-02 | Serbousek Jon C | Polymeric wrap for in vivo delivery of osteoinductive formulations |
US20060057184A1 (en) * | 2004-09-16 | 2006-03-16 | Nycz Jeffrey H | Process to treat avascular necrosis (AVN) with osteoinductive materials |
CN101133084A (zh) * | 2004-12-02 | 2008-02-27 | 多曼蒂斯有限公司 | 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法 |
WO2006074399A2 (fr) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Molecules de liaison multispecifiques comprenant des peptides de connexion |
DE602006017071D1 (de) | 2005-01-25 | 2010-11-04 | Five Prime Therapeutics Inc | Zusammensetzungen und verfahren zur behandlung von herzkrankheiten |
US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
US9119901B2 (en) | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
ES2336832T3 (es) | 2005-07-22 | 2010-04-16 | Five Prime Therapeutics, Inc. | Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr. |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
JP2009506096A (ja) * | 2005-08-30 | 2009-02-12 | ノボ ノルディスク ヘルス ケア アーゲー | ペグ化成長ホルモンの液状調製物 |
US7875623B2 (en) * | 2005-11-22 | 2011-01-25 | Controlled Chemicals, Inc. | Process for reducing contaminating Michael acceptor levels in oxycodone and other compositions |
EP1957537A2 (fr) * | 2005-12-01 | 2008-08-20 | Domantis Limited | Formats d'anticorps a domaine competitif qui lient le recepteur type 1 d'interleukine 1 |
US20070179618A1 (en) * | 2006-01-31 | 2007-08-02 | Sdgi Holdings, Inc. | Intervertebral prosthetic disc |
US20070179615A1 (en) * | 2006-01-31 | 2007-08-02 | Sdgi Holdings, Inc. | Intervertebral prosthetic disc |
TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
US7566565B2 (en) | 2006-03-24 | 2009-07-28 | Syntonix Pharmaceuticals, Inc. | PC5 as a factor IX propeptide processing enzyme |
EP2040757A2 (fr) * | 2006-07-07 | 2009-04-01 | Novo Nordisk Health Care AG | Nouveaux conjugués de protéines et leurs procédés de préparation |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
WO2008051383A2 (fr) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Utilisation de co-solvants d'alcool pour améliorer les rendements de réaction de pegylation |
US8043829B2 (en) * | 2006-10-25 | 2011-10-25 | Amgen Inc. | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression |
HUE033960T2 (en) | 2006-12-08 | 2018-01-29 | Lexicon Pharmaceuticals Inc | Monoclonal Antibodies to ANGPTL3 |
WO2008079677A2 (fr) | 2006-12-20 | 2008-07-03 | Arkema Inc. | Polymères d'encapsulation et/ou de liaison |
US7943728B2 (en) | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
US8183201B2 (en) | 2006-12-26 | 2012-05-22 | National Cheng Kung University | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin |
US8088887B2 (en) | 2007-02-13 | 2012-01-03 | Academia Sinica | Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment |
US8415453B2 (en) | 2007-02-13 | 2013-04-09 | Academia Sinica | Lung cancer-targeted peptides and applications thereof |
GB0708376D0 (en) | 2007-05-01 | 2007-06-06 | Alligator Bioscience Ab | Novel polypeptides and uses thereof |
AU2008262490B2 (en) * | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
EP2203471A2 (fr) | 2007-08-09 | 2010-07-07 | Syntonix Pharmaceuticals, Inc. | Peptides immunomodulateurs |
EP2192924B1 (fr) * | 2007-08-20 | 2017-10-11 | Protalix Ltd. | Conjugués de protéines contenant un saccharide et leurs utilisations |
EP2209494B1 (fr) * | 2007-10-09 | 2016-07-20 | Polytherics Limited | Nouvelles protéines et nouveaux peptides conjugués |
US8541543B2 (en) | 2007-11-20 | 2013-09-24 | Academia Sinica | Peptides specific for hepatocellular carcinoma cells and applications thereof |
WO2009073977A1 (fr) * | 2007-12-13 | 2009-06-18 | Biovectra Inc. | Polypeptides modifiés par technologie de transépissage de protéines |
US9134317B2 (en) * | 2008-01-18 | 2015-09-15 | Alan Kleinfeld | Development and use of cysteine-labeled fluorescent probes of unbound analytes |
TWI489994B (zh) * | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
CA2721229C (fr) | 2008-04-14 | 2022-08-23 | Halozyme, Inc. | Hyaluronidases modifiees et utilisations pour traiter des maladies et des pathologies associees a l'acide hyaluronique |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
WO2009136965A1 (fr) * | 2008-05-06 | 2009-11-12 | Sequella, Inc. | Compositions et procédés comprenant des analogues de la capuramycine |
EP2326349B1 (fr) | 2008-07-21 | 2015-02-25 | Polytherics Limited | Nouveaux réactifs et procédé destiné à conjuguer des molécules biologiques |
EP2161031A1 (fr) * | 2008-09-05 | 2010-03-10 | SuppreMol GmbH | Recepteur Fc-gamma pour le traitement de la sclérose en plaques médiée par les lymphocytes B |
US10040838B2 (en) * | 2008-11-04 | 2018-08-07 | Janssen Pharmaceutica Nv | CRHR2 peptide agonists and uses thereof |
EA022752B1 (ru) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
WO2010112034A2 (fr) | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies |
BRPI1015424B1 (pt) | 2009-06-22 | 2022-01-18 | Burnham Institute For Medical Research | Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição |
US20110097302A1 (en) * | 2009-07-16 | 2011-04-28 | Ta Tung Yuan | Il-1ra-polymer conjugates |
WO2011028229A1 (fr) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Compositions de facteur ix de coagulation et leurs procédés de fabrication et d'utilisation |
JP5734985B2 (ja) * | 2009-09-17 | 2015-06-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法 |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
MX2012005262A (es) | 2009-11-04 | 2012-09-28 | Janssen Pharmaceutica Nv | Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina. |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
US9044436B2 (en) | 2009-12-23 | 2015-06-02 | National Cheng Kung University | Compositions and methods for the treatment of angiogenesis-related eye diseases |
CA2786476A1 (fr) * | 2010-01-14 | 2011-07-21 | Ngm Biopharmaceuticals, Inc. | Methodes de traitement des troubles du metabolisme du glucose |
SI3295957T1 (sl) | 2010-01-15 | 2020-02-28 | Kirin-Amgen, Inc. | Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice |
GB201105584D0 (en) | 2011-04-01 | 2011-05-18 | Imp Innovations Ltd | Cancer methods |
DK2585098T3 (da) | 2010-06-28 | 2014-11-03 | Five Prime Therapeutics Inc | Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser |
US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
WO2012068030A1 (fr) | 2010-11-15 | 2012-05-24 | Five Prime Therapeutics, Inc. | Traitement du cancer par dosages élevés de protéines hybrides de fgfr1 solubles |
JP6033229B2 (ja) | 2010-11-24 | 2016-11-30 | レクシコン ファーマシューティカルズ インコーポレイテッド | Notumペクチンアセチルエステラーゼと結合する抗体 |
US20120183548A1 (en) | 2011-01-14 | 2012-07-19 | Five Prime Therapeutics, Inc. | IL-27 Antagonists for Treating Inflammatory Diseases |
PT3272861T (pt) | 2011-01-20 | 2020-03-26 | Protalix Ltd | Construção de ácido nucleico para expressão de alfα-galactosidase em plantas e células de plantas |
WO2012118778A1 (fr) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Peptides car tronqués, procédés et compositions les utilisant |
CA2830065A1 (fr) | 2011-03-16 | 2012-09-20 | Amgen Inc. | Inhibiteurs puissants et selectifs de nav1.3 et nav1.7 |
AU2012240395B2 (en) | 2011-04-06 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Modulating bacterial MAM polypeptides in pathogenic disease |
CA2837588A1 (fr) | 2011-05-31 | 2012-12-06 | Airware, Inc. | Reetalonnage de capteurs de gaz non dispersif a absorption dans l'infrarouge (ndir) sollicites par absorption |
WO2013009627A2 (fr) | 2011-07-08 | 2013-01-17 | Biogen Idec Hemophilia Inc. | Polypeptides chimériques et hybrides du facteur viii et leurs procédés d'utilisation |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
JP6253578B2 (ja) | 2011-07-22 | 2017-12-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 阻害性抗第xii/xiia因子モノクローナル抗体及びそれらの使用 |
US20130101664A1 (en) | 2011-08-18 | 2013-04-25 | Donald W. Kufe | Muc1 ligand traps for use in treating cancers |
US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
US9243037B2 (en) | 2011-11-10 | 2016-01-26 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
CN104093414A (zh) | 2011-11-29 | 2014-10-08 | 神经噬菌体制药股份有限公司 | 噬菌体的p3作为淀粉样蛋白结合剂的用途 |
CN108997490A (zh) | 2012-01-26 | 2018-12-14 | 克里斯托弗·J·索尔斯 | 肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途 |
EP2623110A1 (fr) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques |
LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
CA2864126A1 (fr) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Proteines de facteur viii de recombinaison |
EP3404105A1 (fr) | 2012-07-06 | 2018-11-21 | Bioverativ Therapeutics Inc. | Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations |
DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
EP2908847B1 (fr) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Procédés d'utilisation d'une dose fixe d'un facteur de coagulation |
EP3943102A1 (fr) | 2012-10-30 | 2022-01-26 | Bioverativ Therapeutics Inc. | Procédé d'utilisation de polypeptide du facteur viii |
US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
EP3907237A1 (fr) | 2012-12-20 | 2021-11-10 | Amgen Inc. | Agonistes du récepteur apj et leurs utilisations |
AU2014224599B2 (en) | 2013-03-08 | 2018-11-08 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
WO2014164394A1 (fr) | 2013-03-11 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Traitement combiné du cancer her2+ utilisant des peptides muc1 et des agents chimiothérapeutiques |
US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
UY35462A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulación de un polipéptido del factor viii. |
RU2015150233A (ru) | 2013-05-01 | 2017-06-02 | Файв Прайм Терапьютикс, Инк. | Способы лечения злокачественной опухоли |
WO2014190147A2 (fr) | 2013-05-23 | 2014-11-27 | Five Prime Therapeutics, Inc. | Méthodes de traitement du cancer |
EA030389B1 (ru) | 2013-05-28 | 2018-07-31 | Проклара Байосайенсиз, Инк. | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ |
KR20160026905A (ko) | 2013-06-28 | 2016-03-09 | 체에스엘 베링 게엠베하 | 인자 xii 억제제 및 c1-억제제를 이용한 병용 치료요법 |
EP3033098B1 (fr) | 2013-08-14 | 2022-06-22 | Bioverativ Therapeutics Inc. | Protéines de facteur viii de recombinaison |
TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子viii-xten融合物及其用途 |
WO2015085276A1 (fr) | 2013-12-06 | 2015-06-11 | Biogen Idec Ma Inc. | Outils pharmacocinétiques de population et leurs utilisations |
TWI700101B (zh) | 2014-03-24 | 2020-08-01 | 美商百歐維拉提夫治療公司 | 凍乾之因子ix調配物 |
CN106456751B (zh) | 2014-03-31 | 2021-02-02 | 安姆根K-A有限公司 | 治疗指甲和头皮银屑病的方法 |
ES2950789T3 (es) | 2014-06-10 | 2023-10-13 | Amgen Inc | Polipéptidos de apelina |
PL3157548T3 (pl) | 2014-06-18 | 2022-01-17 | Csl Behring Gmbh | Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
EP3227313B1 (fr) | 2014-12-03 | 2022-02-09 | Proclara Biosciences, Inc. | Polypeptides comportant une séquence d'acides aminés modifiée de la protéine g3p d'un bactériophage, dépourvue de signal de glycosylation |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
WO2017096262A1 (fr) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions et procédés pour atténuer ou prévenir une réponse immunitaire à une molécule thérapeutique immunogène chez des primates non humains |
US11020160B2 (en) | 2016-03-21 | 2021-06-01 | Warsaw Orthopedic, Inc. | Surgical injection system and method |
MA45473A (fr) | 2016-04-04 | 2019-02-13 | Shire Human Genetic Therapies | Inhibiteur de c1 estérase conjugué et ses utilisations |
WO2017173494A1 (fr) | 2016-04-06 | 2017-10-12 | Csl Limited | Méthode de traitement de l'athérosclérose |
US10709814B2 (en) | 2016-04-22 | 2020-07-14 | Warsaw Orthopedic, Inc. | Osteoimplant comprising an insoluble fibrous polymer |
JP7094223B2 (ja) | 2016-04-25 | 2022-07-01 | ファイブ プライム セラピューティクス, インコーポレイテッド | 病的な筋肉減少および筋力低下の処置のためのnope |
EP4316595A3 (fr) | 2016-09-02 | 2024-04-17 | Christopher J. Soares | Utilisation d'antagonistes du récepteur cgrp pour le traitement du glaucome |
MX2019006446A (es) | 2016-12-02 | 2019-12-11 | Bioverativ Therapeutics Inc | Métodos para inducir tolerancia inmunológica a factores de coagulación. |
EP3548066A1 (fr) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques |
KR20190112763A (ko) | 2017-01-31 | 2019-10-07 | 바이오버라티브 테라퓨틱스 인크. | 인자 ix 융합 단백질 및 이의 제조 및 사용 방법 |
US10294264B2 (en) | 2017-04-21 | 2019-05-21 | Warsaw Orthopedic, Inc. | Oxysterol-therapeutic agent derivative for bone healing |
CA3100071A1 (fr) | 2018-05-16 | 2019-11-21 | Csl Limited | Variants de type 1 du recepteur du complement soluble et utilisations associees |
SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
EP3836954A1 (fr) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci |
WO2023222565A1 (fr) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
IN150740B (fr) | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
US4760067A (en) * | 1979-08-15 | 1988-07-26 | Merck & Co., Inc. | Allylsulfoxide enzyme inhibitors |
EP0040506B1 (fr) | 1980-05-21 | 1986-08-20 | Teijin Limited | Polymère réactif et procédé pour sa préparation |
US4560649A (en) | 1981-10-15 | 1985-12-24 | Cornell Research Foundation | Assaying for hLH or hCG with immobilized hormone receptors |
JPH0751511B2 (ja) | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン2を含有してなる癌治療剤 |
DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
US4587046A (en) | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4966888A (en) | 1985-07-08 | 1990-10-30 | Cornell Research Foundation, Inc. | hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine |
US4522750A (en) | 1984-02-21 | 1985-06-11 | Eli Lilly And Company | Cytotoxic compositions of transferrin coupled to vinca alkaloids |
EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
SE470099B (sv) | 1984-05-17 | 1993-11-08 | Jerker Porath | Sulfonaktiverade tioeteradsorbenter för separation av t ex protein |
US4578335A (en) | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
US4670563A (en) | 1984-06-20 | 1987-06-02 | Sanofi | Imidazolides as intermediates for the synthesis of cytotoxic conjugates |
US4675285A (en) | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
SE454885B (sv) | 1984-10-19 | 1988-06-06 | Exploaterings Ab Tbf | Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
JP2524586B2 (ja) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JPS62185029A (ja) | 1986-02-07 | 1987-08-13 | Ajinomoto Co Inc | 修飾インタ−ロイキン−2 |
CA1283046C (fr) | 1986-05-29 | 1991-04-16 | Nandini Katre | Facteur de necrose des tumeurs |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
IN165717B (fr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4931544A (en) | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
IL80005A (en) | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
US4965271A (en) | 1986-12-31 | 1990-10-23 | Hoechst Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
US5359032A (en) | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
AU633471B2 (en) | 1987-08-26 | 1993-02-04 | Biogen Idec Ma Inc. | Biological materials, processes for producing biological materials and for using such materials in therapy |
IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
US5512544A (en) | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
IL90339A (en) | 1989-05-18 | 1996-10-16 | Yeda Res & Dev | Anti-cytotoxic protein and its purification |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5153265A (en) | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
GB8806339D0 (en) | 1988-03-17 | 1988-04-13 | Hoffmann La Roche | Monoclonal antibodies |
GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
IL89790A (en) | 1988-04-01 | 2002-05-23 | Johns Hopking University | Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification |
US5214131A (en) | 1988-05-06 | 1993-05-25 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, modified peptides and production thereof |
KR0148009B1 (ko) | 1988-05-27 | 1998-08-01 | 그래고리 비. 아보트 | 인터루킨-1 억제제 |
US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
JPH0240399A (ja) | 1988-07-27 | 1990-02-09 | Takeda Chem Ind Ltd | 線維芽細胞増殖因子ムテインの複合体あるいは組成物 |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
US5811261A (en) | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
GB8824592D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Purification process |
GB8824869D0 (en) | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
WO1990005534A1 (fr) | 1988-11-23 | 1990-05-31 | Genentech, Inc. | Derives de polypeptides |
JPH04502469A (ja) | 1988-12-22 | 1992-05-07 | ゾマ コーポレイション | ヒンダードカップリング剤および方法 |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
EP0386289A1 (fr) | 1989-03-07 | 1990-09-12 | Taniguchi, Tadatsugu, Dr. | Récepteur d'interleukine-2 recombinant |
CA2011450C (fr) | 1989-03-07 | 2002-06-04 | Tadatsugu Taniguchi | Chaine beta recombinante du recepteur d'il-2 |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
CA2017025C (fr) | 1989-05-18 | 2008-07-22 | David Wallach | Proteine de liaison ii du facteur de necrose des tumeurs, sa purification et les anticorps diriges contre elle |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
EP0939121B2 (fr) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | Protéines liant le TNF |
ES2103305T3 (es) | 1989-11-29 | 1997-09-16 | Amgen Boulder Inc | Produccion de inhibidor de interleuquina-1 humana recombinada. |
ES2080098T3 (es) | 1989-12-13 | 1996-02-01 | Yeda Res & Dev | Expresion de la proteina de union i al factor de necrosis tumoral tbp-i recombinante. |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
AU649245B2 (en) | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
GB2246569A (en) | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP3693671B2 (ja) | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | ポリペプチドのpeg化 |
DE69213240T2 (de) * | 1991-07-04 | 1997-04-24 | Immunodex K/S, Glostrup | Wasserlösliche reagenzien und konjugate auf polymerbasis, die vom divinylsulfon abgeleitete reste enthalten |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
US5569779A (en) * | 1991-12-23 | 1996-10-29 | Albemarle Corporation | Polyfunctional michael addition products |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
EP0622394A1 (fr) | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Modification reversible de composés contenant du soufre par des glycols de polyalkylène et leur utilisation |
EP0710121B1 (fr) | 1993-07-30 | 2000-10-11 | Kennedy Institute Of Rheumatology | Procede de traitement de la sclerose en plaques |
GB9317618D0 (en) * | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
-
1994
- 1994-06-14 US US08/259,413 patent/US6552170B1/en not_active Expired - Fee Related
-
1995
- 1995-06-14 AU AU28286/95A patent/AU2828695A/en not_active Abandoned
- 1995-06-14 HU HU9603442A patent/HUT77529A/hu unknown
- 1995-06-14 BR BR9507999A patent/BR9507999A/pt unknown
- 1995-06-14 PL PL95317894A patent/PL317894A1/xx unknown
- 1995-06-14 CZ CZ963576A patent/CZ357696A3/cs unknown
- 1995-06-14 EE EE9600182A patent/EE9600182A/xx unknown
- 1995-06-14 SK SK1595-96A patent/SK159596A3/sk unknown
- 1995-06-14 EP EP95923865A patent/EP0758906A1/fr not_active Withdrawn
- 1995-06-14 CA CA002191971A patent/CA2191971C/fr not_active Expired - Fee Related
- 1995-06-14 WO PCT/US1995/007555 patent/WO1995034326A1/fr not_active Application Discontinuation
- 1995-06-14 CN CN95194463A patent/CN1158089A/zh active Pending
-
1996
- 1996-12-12 NO NO965342A patent/NO965342L/no unknown
- 1996-12-12 FI FI964985A patent/FI964985A/fi not_active Application Discontinuation
- 1996-12-30 BG BG101095A patent/BG101095A/xx unknown
-
2003
- 2003-03-27 US US10/401,634 patent/US20030190304A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1995034326A1 (fr) | 1995-12-21 |
EE9600182A (et) | 1998-02-16 |
FI964985A0 (fi) | 1996-12-12 |
HU9603442D0 (en) | 1997-02-28 |
EP0758906A1 (fr) | 1997-02-26 |
FI964985A (fi) | 1996-12-16 |
CN1158089A (zh) | 1997-08-27 |
HUT77529A (hu) | 1998-05-28 |
US20030190304A1 (en) | 2003-10-09 |
PL317894A1 (en) | 1997-04-28 |
SK159596A3 (en) | 1997-08-06 |
NO965342L (no) | 1997-02-14 |
CA2191971C (fr) | 2002-03-05 |
US6552170B1 (en) | 2003-04-22 |
NO965342D0 (no) | 1996-12-12 |
CA2191971A1 (fr) | 1995-12-21 |
CZ357696A3 (en) | 1997-03-12 |
AU2828695A (en) | 1996-01-05 |
BR9507999A (pt) | 1997-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG101095A (en) | Polyethyleneglycolizing reagents and compounds produced by them | |
DE50014571D1 (de) | Träger-pharmaka-konjugate | |
AU3966393A (en) | Biodegradable compositions of synthetic and natural polymers | |
CA2286183A1 (fr) | Nouvelles compositions, et procedes d'inhibition de l'inactivation induite par la lumiere de reactifs biologiques | |
AU5346896A (en) | Heterotelechelic block copolymers and process for producing the same | |
AU9009891A (en) | Acid-labile linker molecules | |
WO1999041273A3 (fr) | Conjugues d'anp et d'adn et procedes de preparation desdits conjugues | |
AU4722096A (en) | Polymerisation in the presence of a beta -substituted nitroxide radical | |
MX9603570A (es) | Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. | |
AU5289096A (en) | Polyethylene oxides having saccharide residue at one end and different functional group at another end, and process for producing the same | |
DE69434649D1 (de) | Durch fluoreszierenden polymer markierte konjugate und zwischen produkte | |
CA2069906A1 (fr) | Polymeres de type morpholino comportant des liaisons entre sous-unites chirales qui contiennent du phosphore | |
WO2002087001A3 (fr) | Membrane a electrolyte polymere | |
WO2005007197A3 (fr) | Molecules biologiques conjuguees et leur preparation | |
BR9812376A (pt) | Uso de um pentopiranosil nucleosìdio para a produção de um componente eletronico, e seus conjugados | |
GR3031200T3 (en) | Transportvehicles for macromolecules | |
CA2273318A1 (fr) | Polysuccinimides de polyalkylene et derives post-traitement de ces produits | |
MXPA03008844A (es) | Sustratos, preparacion y uso. | |
AU3050800A (en) | Functionalised polynucleotide compound, optionally marked and method for detecting a target nucleic acid | |
BR9908410A (pt) | Composição catalisadora e processo para sua preparação | |
EP0343955A3 (fr) | Processus pour lier des complexes d'espèces moléculaires en vue | |
WO1996040664A3 (fr) | Preparations d'immunogenes et d'autres conjugues de medicaments | |
AU2001231973A1 (en) | Method for preparing functionalised beta-(1,3)-glucan derivatives | |
WO2002053091A3 (fr) | Association medicamenteuse d'une biguanine (metformine) et d'arginine | |
RU95110479A (ru) | Способ получения ударопрочного блоксополиэфирамида |